Enhanced STOPP/START Criteria: A Tool for Managing Polypharmacy in Older Population-Reference-Cited by-同舟云学术

Enhanced STOPP/START Criteria: A Tool for Managing Polypharmacy in Older Population

Published:2024-01-17 Issue:4 Volume:16 Page:273-288
ISSN:2686-8709
Container-title:Russian Journal of Geriatric Medicine
language:
Short-container-title:Rossiiskii zhurnal geriatricheskoi meditsiny

Author:

Kotovskaya Yu. V.¹^ORCID,Tkacheva O. N.¹^ORCID,Runikhina N. K.¹^ORCID,Cherniaeva M. S.²^ORCID,Malaya I. P.³^ORCID,Maslennikova O. M.⁴^ORCID,Egorova L. A.⁴^ORCID,Dotsenko A. A.⁴^ORCID

Affiliation:

1. Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center

2. Central State Medical Academy of the Presidential Administration of the Russian Federation; State Budgetary Institution of Health “Hospital for War Veterans No. 2” of the Department of Health of Moscow

3. Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center

4. Central State Medical Academy of the Presidential Administration of the Russian Federation

Abstract

Polypharmacy in geriatric patients is associated with an increased risk of adverse outcomes. Therefore, several instruments for prescription analysis and optimization can be used to enhance the safety and efficacy of pharmacotherapy in old age population. STOPP/START criteria is one of the most popular screening tools in the Russian Federation and abroad that list potentially inappropriate drugs for use in older patients (STOPP criteria) and potentially prescribed for certain clinical cases (START criteria). Two previous versions of the STOPP/START criteria were published in 2008 and 2015. Released in 2023, the newest (third version) demonstrates the evolution of evidence-based pharmacotherapy for older and oldestold patients, featuring 133 STOPP and 57 START criteria. Expanding the base of STOPP/START criteria should support optimization of prescriptions and reducing ADRs risk in older patients. This article introduces translation of STOPP/START criteria, version 3.

Publisher

Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology

Subject

General Materials Science

Reference18 articles.

1. Gutiérrez-Valencia M., Izquierdo M., Cesari M., et al. The relationship between frailty and polypharmacy in older people: Asystematic review. Br J Clin Pharmacol. 2018;84(7):1432-1444. doi: 10.1111/bcp.13590.

2. Maher R.L., Hanlon J., Hajjar E.R. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. doi: https://doi.org/10.1517/14740338.2013.827660.

3. Hein C., Forgues A., Piau A., et al. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014;15(11):850.e11-15. doi: https://doi.org/10.1016/j.jamda.2014.08.012.

4. Machado-Duque M.E, Castaño-Montoya J.P., Medina-Morales D.A, et al. Drugs with Anticholinergic Potential and Risk of Falls with Hip Fracture in the Elderly Patients: A Case-Control Study. J Geriatr Psychiatry Neurol. 2018;31(2):63-69. doi: https://doi.org/10.1016/j.rcp.2020.11.004

5. Hanlon J.T., Handler S.M., Maher R.L., Schmader K.E. Geriatric Pharmacotherapy and Polypharmacy. In: Fillit H.M., Rockwood K., Young J.B. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. 8th ed. Elsevier 2017;849-854.